MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Richard Greil, K Kopeckova, L Arcaini, A Amin, K de Graaf, AM Jegg

    Research output: Contribution to journalpublished Abstract (Journal)peer-review

    Original languageEnglish
    Pages (from-to)S356-S356
    JournalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
    Volume22
    Publication statusPublished - 2022

    Cite this